Compare NBP & YCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBP | YCY |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 151.8M |
| IPO Year | 2019 | 2025 |
| Metric | NBP | YCY |
|---|---|---|
| Price | $0.86 | $10.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 490.7K | 106.7K |
| Earning Date | 08-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $9.90 |
| 52 Week High | $5.19 | $10.33 |
| Indicator | NBP | YCY |
|---|---|---|
| Relative Strength Index (RSI) | 20.57 | 62.89 |
| Support Level | N/A | $9.95 |
| Resistance Level | $1.45 | N/A |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 3.75 | 100.00 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
AA Mission Acquisition Corp II is a blank check company formed for the purpose of effectuating a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities.